MetaVia's DA-1726 Shows Promise at ObesityWeek® 2025 with New Research Presentations
MetaVia's DA-1726 Highlights at ObesityWeek® 2025
MetaVia Inc., a biotechnology company specializing in cardiometabolic disease innovation, has recently informed the public about its exciting new findings regarding DA-1726, a groundbreaking therapeutic candidate designed for obesity treatment.
Overview of the Presentation
The company is set to present two noteworthy abstracts at the upcoming ObesityWeek® 2025 event, scheduled for November 4-7, 2025, in Atlanta, GA. Both presentations will feature DA-1726, a dual agonist of glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR).
The first abstract is titled “Safety, Tolerability, and Pharmacokinetics of DA-1726, an Oxyntomodulin Analogue in a Phase 1 Study.” It will be presented by Dr. Chris Fang, a Consulting Chief Medical Officer at MetaVia. The poster number is P-209 and will be showcased on November 4, 2025, from 7:30 to 8:30 PM ET, in Exhibit Hall A1.
The second abstract, titled “DA-1726, an Oxyntomodulin Analogue: A Promising Therapy for Obesity and Related Metabolic Disorders,” will be introduced by Tae-Hyoung Kim, M.S., Lead Research Scientist at Dong-A ST. This presentation will also occur on November 4, 2025, from 7:30 to 8:30 PM ET, at the same location under poster number P-154.
What is DA-1726?
DA-1726 is an innovative oxyntomodulin analogue that acts as a dual agonist targeting GLP1R and GCGR. This allows it to tackle obesity and conditions like Metabolic Dysfunction-Associated Steatohepatitis (MASH). With a planned weekly subcutaneous administration, DA-1726 has shown potential to significantly aid weight loss by controlling appetite and boosting energy expenditure.
Preclinical models highlighted its efficacy, demonstrating better weight loss outcomes compared to popular treatments like semaglutide (Wegovy®) and cotadutide. Significantly, DA-1726 was not only effective but also managed to preserve lean body mass while improving lipid metabolism compared to other similar medications such as tirzepatide (Zepbound®).
A New Era for Obesity Treatment
The Phase 1 study of DA-1726, specifically the multiple ascending dose (MAD) trial focusing on individuals with obesity, indicated an impressive performance for the 32 mg dose in promoting weight loss, enhancing glucose control, and reducing waist circumference. These results position DA-1726 as a potentially best-in-class treatment option within this domain.
About MetaVia Inc.
MetaVia Inc. stands at the forefront of biotechnology with a commitment to addressing cardiometabolic diseases. Currently, the company is focusing on advancing DA-1726 for obesity management while also developing another therapeutic candidate, Vanoglipel (DA-1241), aimed at treating MASH. This promising pipeline suggests a robust approach to tackling complex metabolic disorders with innovative solutions.
The ongoing research and subsequent presentations at ObesityWeek® 2025 underscore MetaVia's dedication to bringing forward cutting-edge therapies that could redefine treatment standards in the field of obesity and related metabolic issues.
For more details on DA-1726 or to view the presented posters post-conference, interested parties are encouraged to visit MetaVia's website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.